Cybin Inc. shares rise 1.13% intraday after receiving approval to initiate EMBRACE trial in Europe.

Cybin Inc. rose 1.13% in intraday trading, with the company announcing that its Clinical Trial Application ('CTA') has been approved by the Irish Medicines Board to initiate the EMBRACE™ study in Ireland, Poland, and Greece. The company also received approval from the Medical and Healthcare products Regulatory Agency ('MHRA') to commence EMBRACE in the United Kingdom. CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration ('FDA') for the Adjunctive treatment of Major Depressive Disorder ('MDD').